PARG

Poly(ADP-ribose) glycohydrolase

16,372 patent compounds predicted against PARG, 7,575 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2595040	0.53	17/20
SCHEMBL653027	0.43	11/20
SCHEMBL60256	0.72	7/20
SCHEMBL2459264	0.62	7/20
Potassium Ion (SCHEMBL2784885)	0.59	7/20
SCHEMBL2858677	0.59	7/20
Water (SCHEMBL1976332)	0.57	7/20
SCHEMBL919135	0.54	7/20
SCHEMBL626766	0.54	7/20
SCHEMBL2167466	0.53	7/20
Water (SCHEMBL2154885)	0.53	7/20
Water (SCHEMBL1976333)	0.51	7/20
Potassium Ion (SCHEMBL2077835)	0.50	7/20
SCHEMBL3821330	0.50	7/20
SCHEMBL1615844	0.88	6/20
SCHEMBL918573	0.61	6/20
SCHEMBL305527	0.59	6/20
SCHEMBL2517727	0.41	6/20
SCHEMBL2388342	0.38	6/20
SCHEMBL426122	0.54	5/20

Germline variants in PARG on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PARG gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PARG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor	PHASE2	COMPLETED
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients	PHASE2	UNKNOWN
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)	PHASE2	RECRUITING
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction	PHASE1	ACTIVE_NOT_RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway	PHASE1	NOT_YET_RECRUITING
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
Study of AMG 650 in Adult Participants With Advanced Solid Tumors	PHASE1	COMPLETED
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE
PPK Study Based on Quantitative Pharmacology in Patients With Pamipril	nan	UNKNOWN
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PARG binder may also engage these)

Protein	Name	Similarity
O88622	—	1.000	O88622 →
Q9QYM2	—	1.000	Q9QYM2 →
O02776	—	0.999	O02776 →
Q6A037	—	0.988	Q6A037 →
Q8BMI4	—	0.988	Q8BMI4 →
Q4G0A6	—	0.987	Q4G0A6 →
Q5QJC2	—	0.987	Q5QJC2 →
P62287	—	0.987	P62287 →
Q5TKR9	—	0.987	Q5TKR9 →
Q2KIP2	—	0.987	Q2KIP2 →
Q5ZLE9	—	0.987	Q5ZLE9 →
Q5QJC4	—	0.987	Q5QJC4 →
Q08D35	—	0.987	Q08D35 →
P62292	—	0.987	P62292 →
P14629	—	0.987	P14629 →
TOR1AIP1	Torsin-1A-interacting protein 1	0.987	landscape →
Q5PQX1	—	0.987	Q5PQX1 →
P62291	—	0.986	P62291 →
Q80Y19	—	0.986	Q80Y19 →
Q07G43	—	0.986	Q07G43 →
Q92613	—	0.986	Q92613 →
O75113	—	0.986	O75113 →
DCLRE1A	DNA cross-link repair 1A protein	0.986	landscape →
Q6GNV6	—	0.986	Q6GNV6 →
P62297	—	0.986	P62297 →
Q3UQI9	—	0.986	Q3UQI9 →
P62289	—	0.986	P62289 →
Q9JIC3	—	0.986	Q9JIC3 →
Q5T5J6	—	0.986	Q5T5J6 →
P62290	—	0.986	P62290 →